BRAF and melanoma: Several observations focused attention on the immunomodulatory effect of BRAF/MEK inhibitors, that induce an increase of melanoma antigens expression and of CD8+ lymphocyte intratumoral infiltration, and a reduction of the release of several immunosuppresive cytokines [23].